• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Schwaab joins Roswell Park Cancer Institute

Article

Roswell Park Cancer Institute has appointed Thomas Schwaab, MD, PhD, as staff physician and assistant professor of oncology in the departments of urology and immunology. Dr. Schwaab offers laparascopic and robot-assisted surgery to patients with kidney cancer and other genitourinary cancers.

Roswell Park Cancer Institute has appointed Thomas Schwaab, MD, PhD, as staff physician and assistant professor of oncology in the departments of urology and immunology. Dr. Schwaab offers laparascopic and robot-assisted surgery to patients with kidney cancer and other genitourinary cancers.

Dr. Schwaab comes to Roswell Park from the Center for Urologic Care, Concord Hospital, Concord, NH. He also served as an adjunct assistant professor of medicine in the Immunologic Therapy Program, Norris Cotton Cancer Center, Dartmouth Medical School, and an adjunct assistant professor of surgery at the Dartmouth Hitchcock Medical Center, Lebanon, NH.

Dr. Schwaab’s research interests focus on vaccine-based immunotherapy, dendritic cell vaccines, antigen presentation on CD1 molecules, and regulation of T regulatory and T suppressor cells. His clinical research is centered on laparoscopy and robotic surgery.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Gamal M. Ghoniem, MD, FACS, ABU/FPMRS, gives an answer during a video interview
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Zhina Sadeghi, MD, answers a question during a video interview
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
© 2024 MJH Life Sciences

All rights reserved.